Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Atria Investments Inc

Atria Investments Inc raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 49,238 shares of the medical research company's stock after purchasing an additional 2,433 shares during the period. Atria Investments Inc's holdings in Thermo Fisher Scientific were worth $30,457,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Empowered Funds LLC raised its stake in shares of Thermo Fisher Scientific by 53.3% in the first quarter. Empowered Funds LLC now owns 7,704 shares of the medical research company's stock valued at $4,478,000 after buying an additional 2,677 shares during the period. Atomi Financial Group Inc. lifted its stake in shares of Thermo Fisher Scientific by 29.2% during the 1st quarter. Atomi Financial Group Inc. now owns 1,404 shares of the medical research company's stock valued at $816,000 after buying an additional 317 shares in the last quarter. Concurrent Investment Advisors LLC grew its stake in Thermo Fisher Scientific by 9.2% in the 1st quarter. Concurrent Investment Advisors LLC now owns 2,093 shares of the medical research company's stock valued at $1,216,000 after buying an additional 176 shares in the last quarter. Choate Investment Advisors lifted its position in shares of Thermo Fisher Scientific by 37.1% during the first quarter. Choate Investment Advisors now owns 32,544 shares of the medical research company's stock worth $18,915,000 after acquiring an additional 8,806 shares in the last quarter. Finally, NorthRock Partners LLC grew its position in shares of Thermo Fisher Scientific by 34.4% in the first quarter. NorthRock Partners LLC now owns 3,521 shares of the medical research company's stock valued at $2,046,000 after purchasing an additional 902 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 2,000 shares of the firm's stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the sale, the senior vice president now directly owns 12,736 shares in the company, valued at $7,134,197.76. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the completion of the sale, the chief executive officer now directly owns 121,192 shares in the company, valued at approximately $67,175,513.68. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the completion of the sale, the senior vice president now owns 12,736 shares of the company's stock, valued at $7,134,197.76. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,150 shares of company stock valued at $15,676,125. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Down 0.7 %

Shares of Thermo Fisher Scientific stock traded down $4.15 during trading on Friday, reaching $551.74. The company's stock had a trading volume of 1,620,732 shares, compared to its average volume of 1,397,669. The company has a 50-day simple moving average of $593.95 and a two-hundred day simple moving average of $583.69. Thermo Fisher Scientific Inc. has a 1-year low of $437.26 and a 1-year high of $627.88. The company has a market cap of $211.04 billion, a price-to-earnings ratio of 34.59, a P/E/G ratio of 3.65 and a beta of 0.79. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The firm had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. During the same period last year, the firm posted $5.69 EPS. Thermo Fisher Scientific's revenue was up .2% on a year-over-year basis. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be issued a dividend of $0.39 per share. The ex-dividend date is Friday, December 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.78%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on TMO shares. JPMorgan Chase & Co. raised their price target on shares of Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an "overweight" rating in a report on Friday, September 20th. Stephens assumed coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, October 1st. They set an "overweight" rating and a $680.00 price objective on the stock. Royal Bank of Canada lowered their price target on Thermo Fisher Scientific from $767.00 to $718.00 and set an "outperform" rating on the stock in a research report on Thursday, October 24th. Barclays cut their target price on Thermo Fisher Scientific from $620.00 to $610.00 and set an "equal weight" rating for the company in a research note on Wednesday, October 23rd. Finally, TD Cowen upped their price target on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $649.33.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.